Stocks Health care AARD
NASDAQ · Health careAardvark Therapeutics, Inc. (AARD)
It posted a net loss of $69.9M. In fiscal 2025 capital spending exceeded operating cash flow by $54.3M. At June 30, 2026 it held $73.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Aardvark Therapeutics, Inc. does
Aardvark Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AARD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$57.6M | -$2.93 | -$54.3M |
| 2025 | n/a | -$20.6M | -$5.15 | -$18.2M |
Latest SEC filings
What Aardvark Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 17, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- July 10, 2026
- July 10, 2026Proxy statement DEF 14A
- June 29, 2026Preliminary proxy statement PRE 14A
- June 12, 2026
- May 14, 2026Other event 8-K
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
Insider trades
What the people running Aardvark Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $395K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Sun NelsonSee Remarks | Soldpre-planned (10b5-1) | 62,000 | $321.2K |
| September 10, 2026 | Sun NelsonSee Remarks | Soldpre-planned (10b5-1) | 14,754 | $73.8K |
Questions about AARD
What does Aardvark Therapeutics, Inc. do?
Aardvark Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AARD.
Is Aardvark Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $69.9M.
When did Aardvark Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 11, 2026.
Similar companies
Compare AARD with
Follow AARD
Get an email when Aardvark Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AARD: get an email when it filesWhere the numbers come from
Financial figures are the values Aardvark Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.